Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma.

The Journal of investigative dermatology - 1 May 2017

Trousil Sebastian, Chen Shuang, Mu Chan, Shaw Fiona M, Yao Zhan, Ran Yuping, Shakuntala Tiwari, Merghoub Taha, Manstein Dieter, Rosen Neal, Cantley Lewis C, Zippin Jonathan H, Zheng Bin

Abstract excerpt

Inactivation of the tumor suppressor neurofibromin 1 (NF1) presents a newly characterized melanoma subtype, for which currently no targeted therapies are clinically available. Preclinical studies suggest that extracellular signal-regulated kinase (ERK) inhibitors are likely to provide benefit, albeit with limited efficacy as a single agent; therefore, there is a need for rationally designed combination therapies....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Indazoles

Share to Melanoma

Share to Neurofibromin 1

Share to Oxygen Consumption

Share to Piperazines

Source

Open in PubMed Open full text

Identifiers

PMID: 28143781
DOI: 10.1016/j.jid.2017.01.013
PMCID: PMC5392423

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma.PMID 28143781Read ↗

Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.Semantic proximity Read ↗

Systematic analysis uncovers SYK dependency in NF1 <sup>LoF</sup> melanoma cellsSemantic proximity Read ↗

Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibitionSemantic proximity Read ↗

NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma.Semantic proximity Read ↗

Simvastatin reprograms lipid metabolism in B16.F10 melanoma cells to favor an early resistant phenotype.Semantic proximity Read ↗

Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN lossSemantic proximity Read ↗

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells.Semantic proximity Read ↗

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.Semantic proximity Read ↗

Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma.Semantic proximity Read ↗

Loss of AMPKα2 promotes melanoma tumor growth and brain metastasisSemantic proximity Read ↗

Targeting CPT1A enhances metabolic therapy in human melanoma cells with the BRAF V600E mutation.Semantic proximity Read ↗

Metabolism-oriented compound screen in physiological culture conditions identifies a NAMPT inhibitor highly effective against drug-naïve and -resistant melanoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.